To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.
|Original language||English (US)|
|Number of pages||3|
|Journal||Critical Care Medicine|
|State||Published - 1990|
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine